(Date:11/6/2009)...G VALLEY, Calif., Nov. 6 Calbiotec... Small Business Innovative Research (SBIR) Phase I...terial command. Under terms of the agreement, Calb...s) for the diagnosis of Dengue virus. ,, Den...sents a major threat to military forces deployed t...
(Date:11/5/2009)...ERSBURG, Md., Nov. 5 Gen...ancial results for the third quarter ended Septemb...llion ($0.04 per share) for the three months ended... million ($0.08 per share) in the comparable quart..., 2009, GenVec,s net loss was $14.1 million ($0.15...
(Date:11/5/2009)...rence Call on Thursday, November 5, 2009 at 4:30 p...Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmace...AQ: OGXI ) today reported unaudited financial res...eptember 30, 2009 and reviewed the Company,s highl...lowing consolidated results reflect the operations...
(Date:11/5/2009)...IEGO, CA, November 5, 2009 /PRNewswire-FirstCall/ ...ed on using proprietary taste receptor-based techn...he food, beverage, and ingredient supply industrie...financial results for the third quarter ended Sept...e third quarter of 2009, compared to $4.0 million ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2Fingerprinting II Database Sharing Tools from Bio-Rad
Fingerprinting II Identification and Library Manager from Bio-Rad
DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
...High Quality, Functionally-Validated, Ion Channel ...ng a critical role in nerve and muscle function an...d the heart. Drugs that modulate ion channels have...europathic pain, cardiac arrhythmia, hypertension,...
Biology Products: